E-LIB Suche - Ergebnisse für: Marco, Donia

1

ITOC2 – 009. Role of signal transduction and microRNAs on t..:

Stefanie, Meyer ; Marco, Donia ; Diana, Handke...
European Journal of Cancer. 51 (2015) - p. S3 , 2015

2

Outcome of adjuvant immunotherapy in a real-world nation-wi..:

Holmstroem, Rikke B. ; Pedersen, Sidsel ; Jurlander, Rebecca...
European Journal of Cancer. 202 (2024) - p. 114023 , 2024

Link: https://doi.org/10.1016/..

3

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Po..:

Homburg, Sif ; Christensen, Charlotte Birk ; Pedersen, Magnus...
Cancers. 16 (2024) 5 - p. 964 , 2024

Link: https://doi.org/10.3390/..

4

IMPROVE: a feature model to predict neoepitope immunogenici..:

Borch, Annie ; Carri, Ibel ; Reynisson, Birkir...
Frontiers in Immunology. 15 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

5

Harnessing neoantigen-specific T cells for precision cancer..:

Donia, Marco ; Svane, Inge Marie
Nature Reviews Clinical Oncology. 21 (2024) 4 - p. 253-254 , 2024

Link: https://doi.org/10.1038/..

6

Dose escalation study of a personalized peptide-based neoan..:

Mørk, Sofie Kirial ; Skadborg, Signe Koggersbøl ; Albieri, Benedetta...
Journal for ImmunoTherapy of Cancer. 12 (2024) 5 - p. e008817 , 2024

Link: https://doi.org/10.1136/..

7

Biomarkers for response to TIL therapy: a comprehensive rev..:

Albarrán Fernández, Víctor ; Ballestín Martínez, Pablo ; Stoltenborg Granhøj, Joachim...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e008640 , 2024

Link: https://doi.org/10.1136/..

8

Molecular patterns of resistance to immune checkpoint block..:

Lauss, Martin ; Phung, Bengt ; Borch, Troels Holz...
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

9

Dissecting tumor microenvironment heterogeneity in syngenei..:

Carretta, Marco ; Thorseth, Marie-Louise ; Schina, Aimilia...
Frontiers in Immunology. 14 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

10

Cost-effectiveness of treating advanced melanoma with tumor..:

ten Ham, Renske M T ; Rohaan, Maartje W ; Jedema, Inge...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e008372 , 2024

Link: https://doi.org/10.1136/..

11

PD-L1 is a biomarker of real-world clinical outcomes for an..:

Ellebaek, Eva ; Khan, Shawez ; Bastholt, Lars...
European Journal of Cancer. 198 (2024) - p. 113476 , 2024

Link: https://doi.org/10.1016/..

12

Corrigendum: Ex vivo modulation of intact tumor fragments w..:

Hulen, Thomas Morgan ; Friese, Christina ; Kristensen, Nikolaj Pagh...
Frontiers in Immunology. 15 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

13

Efficacy of Ipilimumab and Nivolumab in Patients with Melan..:

Kattenhøj, Karoline Dreyer ; Møberg, Christine Louise ; Guldbrandt, Louise Mahncke...
Cancers. 16 (2024) 14 - p. 2559 , 2024

Link: https://doi.org/10.3390/..

14

Phase 2 study of ipilimumab, nivolumab, and tocilizumab com..:

Chen, Inna M. ; Donia, Marco ; Chamberlain, Christopher A....
European Journal of Cancer. 180 (2023) - p. 125-133 , 2023

Link: https://doi.org/10.1016/..

15

TCR-engaging scaffolds selectively expand antigen-specific ..:

Tvingsholm, Siri Amanda ; Frej, Marcus Svensson ; Rafa, Vibeke Mindahl...
Journal for ImmunoTherapy of Cancer. 11 (2023) 8 - p. e006847 , 2023

Link: https://doi.org/10.1136/..